Dendreon Corporation Files Registration for Proposed Initial Public Offering.Business Editors SEATTLE--(BUSINESS WIRE)--March 8, 2000 Dendreon Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission for an initial public offering of its common stock. The number of shares to be sold and the estimated price range have not yet been determined. The offering will be lead-managed by Prudential Vector Healthcare Group, a unit of Prudential Securities Incorporated, and co-managed by SG Cowen Securities Corporation and Pacific Growth Equities, Inc. Dendreon Corporation, based in Seattle, Washington  This page is protected from moves until disputes have been resolved on the .The reason for its protection is listed on the protection policy page. , discovers and develops immunologically based therapeutic products for the treatment of cancer. Dendreon is focused on the development of therapeutic vaccines for the treatment of cancer using antigen engineering and proprietary cell separation technologies. The Company is conducting a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for Provenge(TM), its prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. vaccine, and Phase II clinical trials for its multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility vaccine. A copy of the preliminary prospectus Preliminary Prospectus A first draft registration statement filed by a firm prior to proceeding with an initial public offering of securities. The document, filed with the Securities & Exchange Commission, is intended to provide pertinent information to prospective shareholders relating to these securities may be obtained, when available, from Prudential Securities, 111 8th Avenue, 5th Floor, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York 1001. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under securities laws or any such state or jurisdiction. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion